Small and medium diameter veins such as reticular veins and spider veins are generally too small to be treated using current ambulatory phlebectomy techniques. This led the founders of VenX to seek ways to improve those ambulatory phlebectomy techniques for use in treating smaller diameter reticular and spider veins. Their work has led them to the invention of Nanophlebectomy.
The key differentiating factor between the Nanophlebectomy technique and sclerotherapy is that there is no injection of a sclerotherapy agent, and thus the downside of sclerotherapy is averted. In particular, like standard phlebectomy, it is expected that there will be no staining, matting or potential for ulceration as one sees with sclerotherapy.
Nanophlebectomy can be used as an adjunct treatment to other typical vein therapies including endovenous ablation, traditional phlebectomy, and even in combination with sclerotherapy.